Literature DB >> 26556476

Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation--Interim Analysis of the German OCUM Trial (NCT01325649).

Martin E Kreis1,2, R Ruppert3, H Ptok4, J Strassburg5, P Brosi6, A Lewin7, M R Schön8, J Sauer9, T Junginger10, S Merkel11, P Hermanek11.   

Abstract

INTRODUCTION: Introduction of total mesorectal excision (TME) surgery for rectal cancer decreased local recurrence dramatically. Additional neoadjuvant chemoradiation (nCR) is frequently given in UICC II and III tumors based on TNM staging which is of limited accuracy. We aimed to evaluate determination of circumferential margin by magnetic resonance imaging (mrCRM) as an alternative criterium for nCR.
METHODS: Multicenter prospective cohort study which enrolled 642 patients in 13 centers with non-metastasized rectal adenocarcinoma. Patients with T4 tumors or patients with a mrCRM of 1 mm or less were treated by neoadjuvant chemoradiation. All others proceeded directly to surgery when inclusion criteria and no exclusion criteria were met. Quality of TME and accuracy of mrCRM determination were assessed during pathology workup.
RESULTS: TME was complete in 381 of 389 patients after surgery without nCR (97.9%) and in 245 of 253 patients (96.8%) after nCR. Negative pathology circumferential margins (pCRM) were seen in 97.4% without nCR and in 89% of patients after nCR. Negative pCRM was predicted by negative mrCRM in 98.3% of rectal cancers. NCR was given to 253 of 642 patients (39.5%). Lymph node count was 23 (range 7-79; median/range) for surgery without nCR and 19 (range 2-56) for surgery after nCR.
CONCLUSIONS: Surgical quality determined by pathology workup of specimen was very good in this study. Magnetic resonance imaging guided indication for nCR allows to achieve superb results concerning surrogate parameters for good oncological outcome. Thus, use of neoadjuvant chemoradiation with its potential detrimental side effects may be substantially reduced in selected patients.

Entities:  

Keywords:  Magnetic resonance imaging; Multimodal treatment; Neoadjuvant; Quality; Rectal cancer

Mesh:

Year:  2015        PMID: 26556476     DOI: 10.1007/s11605-015-3011-0

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  34 in total

1.  Long-term effect of preoperative radiation therapy on anorectal function.

Authors:  Johan Pollack; Torbjörn Holm; Björn Cedermark; Bo Holmström; Anders Mellgren
Journal:  Dis Colon Rectum       Date:  2006-03       Impact factor: 4.585

2.  [S3-guideline colorectal cancer version 1.0].

Authors:  C Pox; S Aretz; S C Bischoff; U Graeven; M Hass; P Heußner; W Hohenberger; A Holstege; J Hübner; F Kolligs; M Kreis; P Lux; J Ockenga; R Porschen; S Post; N Rahner; A Reinacher-Schick; J F Riemann; R Sauer; A Sieg; W Scheppach; W Schmitt; H J Schmoll; K Schulmann; A Tannapfel; W Schmiegel
Journal:  Z Gastroenterol       Date:  2013-08-16       Impact factor: 2.000

3.  Prospective Validation of a Low Rectal Cancer Magnetic Resonance Imaging Staging System and Development of a Local Recurrence Risk Stratification Model: The MERCURY II Study.

Authors:  Nicholas J Battersby; Peter How; Brendan Moran; Sigmar Stelzner; Nicholas P West; Graham Branagan; Joachim Strassburg; Philip Quirke; Paris Tekkis; Bodil Ginnerup Pedersen; Mark Gudgeon; Bill Heald; Gina Brown
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

Review 4.  Preoperative staging of rectal cancer: the MERCURY research project.

Authors:  G Brown; I R Daniels
Journal:  Recent Results Cancer Res       Date:  2005

5.  Prognostic groups in 1,676 patients with T3 rectal cancer treated without preoperative radiotherapy.

Authors:  Morten T Eriksen; Arne Wibe; Jon Haffner; Johan N Wiig
Journal:  Dis Colon Rectum       Date:  2007-02       Impact factor: 4.585

Review 6.  [Rectal carcinoma: is too much neoadjuvant therapy performed? Proposals for a more selective MRI based indication].

Authors:  Th Junginger; P Hermanek; K Oberholzer; H Schmidberger
Journal:  Zentralbl Chir       Date:  2006-08       Impact factor: 0.942

7.  Quantitative short-term study of anal sphincter function after chemoradiation for rectal cancer.

Authors:  P Gervaz; N Rotholtz; M Pisano; E Kaplan; M Secic; P Coucke; A Pikarsky; J Efron; E Weiss; S Wexner
Journal:  Arch Surg       Date:  2001-02

Review 8.  Colorectal carcinoma: diagnostic, prognostic, and molecular features.

Authors:  Carolyn C Compton
Journal:  Mod Pathol       Date:  2003-04       Impact factor: 7.842

9.  Magnetic resonance imaging (MRI)-based indication for neoadjuvant treatment of rectal carcinoma and the surrogate endpoint CRM status.

Authors:  Joachim Strassburg; Theo Junginger; Trong Trinh; Olaf Püttcher; Katja Oberholzer; Richard J Heald; Paul Hermanek
Journal:  Int J Colorectal Dis       Date:  2008-07-17       Impact factor: 2.571

10.  MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?

Authors:  S Burton; G Brown; I R Daniels; A R Norman; B Mason; D Cunningham
Journal:  Br J Cancer       Date:  2006-02-13       Impact factor: 7.640

View more
  13 in total

Review 1.  [Evidence-based surgery of rectal cancer].

Authors:  M Grade; H Flebbe; B M Ghadimi
Journal:  Chirurg       Date:  2019-05       Impact factor: 0.955

2.  [Transanal total mesorectal excision : A useful complementary method for minimally invasive surgery of rectal cancer].

Authors:  A D Rink; F Aigner; M Biebl; A Fürst; W Kneist
Journal:  Chirurg       Date:  2019-06       Impact factor: 0.955

3.  Clinically Node Negative, Pathologically Node Positive Rectal Cancer Patients Who Did Not Receive Neoadjuvant Therapy.

Authors:  Nouf Akeel; Nan Lan; Luca Stocchi; Meagan M Costedio; David W Dietz; Emre Gorgun; Matthew F Kalady; Georgios Karagkounis; Hermann Kessler; Feza H Remzi
Journal:  J Gastrointest Surg       Date:  2016-10-27       Impact factor: 3.452

4.  Addition of Platinum Derivatives to Fluoropyrimidine-Based Neoadjuvant Chemoradiotherapy for Stage II/III Rectal Cancer: Systematic Review and Meta-Analysis.

Authors:  Felix J Hüttner; Pascal Probst; Eva Kalkum; Matthes Hackbusch; Katrin Jensen; Alexis Ulrich; Jürgen Debus; Dirk Jäger; Markus K Diener
Journal:  J Natl Cancer Inst       Date:  2019-09-01       Impact factor: 13.506

5.  Multimodal Treatment of cT3 Rectal Cancer in a Prospective Multi-Center Observational Study: Can Neoadjuvant Chemoradiation Be Omitted in Patients with an MRI-Assessed, Negative Circumferential Resection Margin?

Authors:  Henry Ptok; Frank Meyer; Ingo Gastinger; Benjamin Garlipp
Journal:  Visc Med       Date:  2021-05-21

6.  Role of the status of the mesorectal fascia in the selection of patients with rectal cancer for preoperative radiation therapy: a retrospective cohort study

Authors:  Marko Simunovic; Vanja Grubac; Kevin Zbuk; Raimond Wong; Angela Coates
Journal:  Can J Surg       Date:  2018-10-01       Impact factor: 2.089

7.  Safety and Feasibility of Using Magnetic Resonance Imaging Criteria to Identify Patients With "Good Prognosis" Rectal Cancer Eligible for Primary Surgery: The Phase 2 Nonrandomized QuickSilver Clinical Trial.

Authors:  Erin D Kennedy; Marko Simunovic; Kartik Jhaveri; Richard Kirsch; Jim Brierley; Sébastien Drolet; Carl Brown; Patrick M Vos; Wei Xiong; Tony MacLean; Selliah Kanthan; Peter Stotland; Simon Raphael; Gil Chow; Catherine A O'Brien; Charles Cho; Cathy Streutker; Raimond Wong; Selina Schmocker; Sender Liberman; Caroline Reinhold; Neil Kopek; Victoria Marcus; Alexandre Bouchard; Caroline Lavoie; Stanislas Morin; Martine Périgny; Ann Wright; Katerina Neumann; Sharon Clarke; Nikhilesh G Patil; Thomas Arnason; Lara Williams; Robin McLeod; Gina Brown; Alex Mathieson; Amandeep Pooni; Nancy N Baxter
Journal:  JAMA Oncol       Date:  2019-07-01       Impact factor: 31.777

Review 8.  Addition of platinum derivatives to neoadjuvant single-agent fluoropyrimidine chemoradiotherapy in patients with stage II/III rectal cancer: protocol for a systematic review and meta-analysis (PROSPERO CRD42017073064).

Authors:  Felix J Hüttner; Pascal Probst; Eva Kalkum; Matthes Hackbusch; Katrin Jensen; Alexis Ulrich; Markus W Büchler; Markus K Diener
Journal:  Syst Rev       Date:  2018-01-22

Review 9.  Organ preservation in rectal cancer - Challenges and future strategies.

Authors:  C Gani; P Bonomo; K Zwirner; C Schroeder; A Menegakis; C Rödel; D Zips
Journal:  Clin Transl Radiat Oncol       Date:  2017-03-23

10.  Influence of complete administration of adjuvant chemotherapy cycles on overall and disease-free survival in locally advanced rectal cancer: post hoc analysis of a randomized, multicenter, non-inferiority, phase 3 trial.

Authors:  Flavius Sandra-Petrescu; Florian Herrle; Iris Burkholder; Peter Kienle; Ralf-Dieter Hofheinz
Journal:  BMC Cancer       Date:  2018-04-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.